LIN-2102

Primary Objective: To evaluate the preliminary efficacy of SLN12140 in PNH subjects after subcutaneous injection. Secondary Objectives: To evaluate other efficacy endpoints of SLN12140 in PNH subjects after subcutaneous injection; to evaluate the safety and tolerability of SLN12140 in PNH subjects after subcutaneous injection; to evaluate the pharmacokinetic (PK) characteristics of SLN12140 in PNH subjects after subcutaneous injection; to evaluate the pharmacodynamic (PD) characteristics of SLN12140 in PNH subjects after subcutaneous injection; to evaluate the immunogenicity of SLN12140 in PNH subjects after subcutaneous injection. Exploratory Objective: Where data permits, to preliminarily establish a population pharmacokinetic (Pop-PK) model of SLN12140, obtain population PK parameters, and preliminarily explore covariates and exposure-response (E-R) relationships that may affect individual PK parameters.